Viking Therapeutics highlights clinical data from VK2735 obesity program at ObesityWeek
VKTX•Viking Therapeutics said VK2735 improved multiple cardiometabolic markers, and 74% of participants improved their BMI category after 13 weeks.
VKTX•VKTX•VKTX•Viking Therapeutics said VK2735 improved multiple cardiometabolic markers, and 74% of participants improved their BMI category after 13 weeks.
Viking Therapeutics highlighted clinical data from its VK2735 obesity program at ObesityWeek 2026. The company said treatment improved multiple cardiometabolic markers and 74% of participants improved their BMI category after 13 weeks.
